Search results (123)
« Back to NewsOchre Bio has announced the launch of its ‘Liver ICU’ in the US to Evaluate Effects of RNA Therapies on Human Liver Performance
10 May 2022
This research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
Nucleome Therapeutics shortlisted as a finalist for the 2022 Oxfordshire Business Awards
9 May 2022
Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.
PepGen Announces Pricing of Initial Public Offering
4 May 2022
The shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol “PEPG.” The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.
Kyttaro enters Worldwide Exclusive Licensing Agreement with Eli Lilly for Antibody Therapeutic Programme
10 April 2022
The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
PepGen announced its first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy
5 April 2022
Initiation of Phase 1 Study marks PepGen’s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
25 January 2022
The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.
Kyttaro Announces an Exclusive Worldwide Licensing Agreement with Oxford University Innovation
3 January 2022
Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust
14 December 2021
The two companies share the same goals, to improve the lives of those dealing with liver disease.
Exact Sciences Innovation graduates to The Oxford Science Park
22 November 2021
Helping people get the answers they need to make more informed decisions across the cancer continuum.
Introducing CyanoCapture
15 November 2021
CyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.
Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics
5 November 2021
The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.
Introducing Kyttaro
1 November 2021
Kyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
Ochre Bio shortlisted as an OBN Awards 2021 finalist in the BioSeed ‘One to Watch’ Category
21 October 2021
Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
PepGen announces closing of $112.5M crossover financing to advance transformative therapies for neuromuscular diseases
4 August 2021
Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
Theolytics graduates from the BioEscalator
22 July 2021
After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
MediMabBio establishes a bridgehead for the development of immuno-oncology drugs in the UK
24 June 2021
MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
Ochre Bio Raises $9.6M to Advance RNA Therapies for Liver Diseases
17 June 2021
The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
Introducing OxVax
13 June 2021
OXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020
10 June 2021
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
MoA Technology graduates from The BioEscalator
31 May 2021
MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.